---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000091"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:09:49.371481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker

## Summary
- Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.
- Cash and equivalents $714M as of March 31, 2025; runway through GD readout expected in 2027.
- Eric Venker, M.D. appointed CEO and Tiago Girao CFO in April 2025 as part of strategic transition.
- R&D expenses $93.7M in Q4, up from $66.1M, driven by IMVT-1402 clinical trial costs.
- Potentially registrational trials for IMVT-1402 in Sjögren's disease and second GD trial planned summer 2025.

## SEC filing metadata
- accession: 0001764013-25-000091
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/0001764013-25-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/imvt-20250529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000091
- JSON: https://secwatch.observer/filing/0001764013-25-000091.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.